StreetInsider.com News Articles

Tango Therapeutics Inc. (TNGX) PT Raised to $40 at Mizuho

Fri, 17 Jul 2026 06:39:00 -0400

(Updated - July 17, 2026 6:39 AM EDT)

Mizuho analyst Joseph Catanzaro raised the price target on Tango Therapeutics Inc. (NASDAQ: TNGX) to $40.00 (from $36.00) while maintaining a Outperform rating.

The analyst commented: "Following the recently presented data for RVMD's (Outperform, PT $215,) daraxonrasib + zoldonrasib in 2L+ PDAC that we believe underscores the unprecedented synergy being observed with darax + TNGX's vopimetostat, along with recent positive KOL feedback, we take our PT to $40 from $36 as we incrementally take up peak 1L PDAC penetration. More details below but (1) PFS comps (see figure below) point to best-in-indication durability; (2)

Tango Therapeutics Inc. (TNGX) PT Raised to $40 at Mizuho

Fri, 17 Jul 2026 06:39:00 -0400

(Updated - July 17, 2026 6:39 AM EDT)

Mizuho analyst Joseph Catanzaro raised the price target on Tango Therapeutics Inc. (NASDAQ: TNGX) to $40.00 (from $36.00) while maintaining a Outperform rating.

JPMorgan Starts Tango Therapeutics Inc. (TNGX) at Overweight

Wed, 15 Jul 2026 03:01:06 -0400

JPMorgan analyst Brian Cheng initiates coverage on Tango Therapeutics Inc. (NASDAQ: TNGX) with a Overweight rating and a price target of $46.00.

The analyst comments: “We initiate coverage on TNGX with an OW rating and a Dec-2026 price target of $46. Following its monotherapy PoC last year with lead PRMT5i vopimetostat, Tango is leading the way in PDAC and potentially NSCLC through its combo trials with RAS inhibitors daraxonrasib and zoldonrasib. The first look at the combo data earlier this year with RVMD’s dara showed impressive response previously unheard of in the 2L+ PDAC setting with a 92% ORR and 6-month

JPMorgan Starts Tango Therapeutics Inc. (TNGX) at Overweight

Wed, 15 Jul 2026 03:01:06 -0400

JPMorgan analyst Brian Cheng initiates coverage on Tango Therapeutics Inc. (NASDAQ: TNGX) with a Overweight rating and a price target of $46.00.

Form 4 Tango Therapeutics, Inc. For: Jul 01 Filed by: Crystal Adam

Thu, 02 Jul 2026 19:24:00 -0400

si-local-file:///var/storage/secattach/20260702/26730097.html

Form 4 Tango Therapeutics, Inc. For: Jul 01 Filed by: Crystal Adam

Thu, 02 Jul 2026 19:24:00 -0400

si-local-file:///var/storage/secattach/20260702/26730097.html

Tango Therapeutics Inc. (TNGX) PT Raised to $46 at Canaccord

Mon, 29 Jun 2026 04:06:17 -0400

Canaccord analyst John Newman raised the price target on Tango Therapeutics Inc. (NASDAQ: TNGX) to $46.00 (from $42.00) while maintaining a Buy rating.

Jefferies Upgrades Tango Therapeutics Inc. (TNGX) to Buy

Thu, 25 Jun 2026 16:04:20 -0400

(Updated - June 25, 2026 4:04 PM EDT)

Jefferies analyst Maury Raycroft upgraded Tango Therapeutics Inc. (NASDAQ: TNGX) from Hold to Buy with a price target of $60.00 (from $27.00).

The analyst commented: "We're upgrading TNGX after stress-testing early 2L/3L PDAC PFS data, which we believe is tracking to ~13mos mPFS, well above daraxonrasib's 8.1mos. We're now modeling ~15mos duration of tx in 1L (~$3.3B peak rev) & ~13mos in 2L (~$1.2B peak rev). Med conf update later in 2026 will provide ~2x larger 'n' to confirm high ORR (vs initial 92%) & refine mPFS est. ESMO GI zoldon+dara/chemo data highlight differentiation

Jefferies Upgrades Tango Therapeutics Inc. (TNGX) to Buy

Thu, 25 Jun 2026 16:04:20 -0400

(Updated - June 25, 2026 4:04 PM EDT)

Jefferies analyst Maury Raycroft upgraded Tango Therapeutics Inc. (NASDAQ: TNGX) from Hold to Buy with a price target of $60.00 (from $27.00).

Jefferies Upgrades Tango Therapeutics Inc. (TNGX) to Buy

Thu, 25 Jun 2026 16:04:20 -0400

(Updated - June 25, 2026 4:04 PM EDT)

Jefferies analyst Maury Raycroft upgraded Tango Therapeutics Inc. (NASDAQ: TNGX) from Hold to Buy with a price target of $60.00 (from $27.00).

Form 4 Tango Therapeutics, Inc. For: Jun 19 Filed by: Azelby Robert

Tue, 23 Jun 2026 18:11:00 -0400

si-local-file:///var/storage/secattach/20260623/26680830.html

Form 4 Tango Therapeutics, Inc. For: Jun 19 Filed by: Azelby Robert

Tue, 23 Jun 2026 18:11:00 -0400

si-local-file:///var/storage/secattach/20260623/26680830.html

Form 3 Tango Therapeutics, Inc. For: Jun 19 Filed by: Azelby Robert

Tue, 23 Jun 2026 18:04:00 -0400

si-local-file:///var/storage/secattach/20260623/26680818.html

Form 3 Tango Therapeutics, Inc. For: Jun 19 Filed by: Azelby Robert

Tue, 23 Jun 2026 18:04:00 -0400

si-local-file:///var/storage/secattach/20260623/26680818.html

Form 8-K Tango Therapeutics, Inc. For: Jun 19

Tue, 23 Jun 2026 17:19:00 -0400

si-local-file:///var/storage/secattach/20260623/26680578.html

Form 8-K Tango Therapeutics, Inc. For: Jun 19

Tue, 23 Jun 2026 17:19:00 -0400

si-local-file:///var/storage/secattach/20260623/26680578.html

Tango Therapeutics adds Robert Azelby to its board of directors

Mon, 22 Jun 2026 16:05:31 -0400

Tango Therapeutics, Inc. (NASDAQ: TNGX) announced the appointment of Robert Azelby to its board of directors, according to a company press release.

Azelby brings more than 30 years of experience in the biopharmaceutical industry, including roles in oncology commercialization and corporate strategy. He previously served as president and chief executive officer of Eliem Therapeutics from October 2020 to February 2023, and as CEO of Alder BioPharmaceuticals from June 2018 until its acquisition by H. Lundbeck in 2019. He also served as executive vice president and chief commercial officer of Juno Therapeutics until its acquisition by Celgene in 2018.

Earlier in his career,

Tango Therapeutics Appoints Robert Azelby to Board of Directors

Mon, 22 Jun 2026 16:05:00 -0400

BOSTON, June 22, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced the appointment of Robert Azelby to its Board of Directors. Mr. Azelby brings more than three decades of leadership experience across the biopharmaceutical industry, including deep expertise in oncology commercialization, corporate strategy, company building and board governance. His appointment comes as Tango advances vopimetostat, its investigational PRMT5 inhibitor with first- and best-in-class potential, toward potential late-stage development for patients with pancreatic cancer.

“As Tango continues to evolve

Tango Therapeutics Appoints Robert Azelby to Board of Directors

Mon, 22 Jun 2026 16:05:00 -0400

“As Tango continues to evolve

Form 144 Tango Therapeutics, Inc. Filed by: NEXTECH CROSSOVER I SCSP

Wed, 17 Jun 2026 16:46:00 -0400

si-local-file:///var/storage/secattach/20260617/26660657.html

Form 144 Tango Therapeutics, Inc. Filed by: NEXTECH CROSSOVER I SCSP

Wed, 17 Jun 2026 16:46:00 -0400

si-local-file:///var/storage/secattach/20260617/26660657.html

Form 144 Tango Therapeutics, Inc. Filed by: Beckman Daniella

Thu, 11 Jun 2026 18:01:00 -0400

si-local-file:///var/storage/secattach/20260611/26637009.html

Form 144 Tango Therapeutics, Inc. Filed by: Beckman Daniella

Thu, 11 Jun 2026 18:01:00 -0400

si-local-file:///var/storage/secattach/20260611/26637009.html

Form 8-K Tango Therapeutics, Inc. For: Jun 09

Wed, 10 Jun 2026 17:22:00 -0400

si-local-file:///var/storage/secattach/20260610/26630934.html

Form 8-K Tango Therapeutics, Inc. For: Jun 09

Wed, 10 Jun 2026 17:22:00 -0400

si-local-file:///var/storage/secattach/20260610/26630934.html